MutualFundWire.com
The insiders' edge for 40 Act industry executives!
an InvestmentWires' Publication
an InvestmentWires' Publication
|
|
MutualFundWire.com
The insiders' edge for 40 Act industry executives!
an InvestmentWires' Publication |
|
Friday, March 22, 2002 Fido Creates Biotech Group Fidelity is taking the collapse of the venture capital market as an opportunity to make lemonade from lemons. The effort features a distinctly Twenty First Century twist with a focus on biotech rather than silicon tech. To spearhead the effort the Boston Behemoth hired David A. Lowe as its new chief scientific officer and executive vice president for its Biosciences Group. Lowe is a former neurobiologist with the US unit of Swiss drug giant Roche Group. Mark Peterson is president of the group and Jason Rhodes a principal. Fidelity has yet to make any investments through the group. Printed from: MFWire.com/story.asp?s=2141 Copyright 2002, InvestmentWires, Inc. All Rights Reserved |